
|Videos|February 13, 2014
Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer
Author(s)Dawn Hershman, MD, MS
Dawn Hershman, MD, MS, medical oncologist, Columbia University Medical Center, discusses chemotherapy-induced peripheral neuropathy in breast cancer.
Advertisement
Clinical Pearls
Dawn Hershman, MD, MS, medical oncologist, Columbia University Medical Center, discusses chemotherapy-induced peripheral neuropathy in breast cancer.
- Chemotherapy-induced neuropathy is the most common dose-limiting side effect and there are not any effective therapies for treatment or prevention
- Patients take a variety of supplements or drugs in the hopes that it will help reduce the neuropathy
- Preclinical data has shown that patients who were taking supplements actually had worse neuropathy compared to patients who were taking a placebo
- Researchers analyzed carnitine levels in the blood to ensure that patients took the supplements​
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Targeting HER2-Low Breast Cancer: the ARX788 Phase 2 Clinical Trial
4
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
5








































